Sanofi Announces Delays in Submission of Tolébrutinib
Sanofi anticipates delays in the regulatory process for tolébrutinib, a treatment for non-relapsing secondary progressive multiple sclerosis, expected by the first quarter of 2026.
Extended Regulatory Review Expected
Sanofi anticipates that the ongoing U.S. regulatory review for tolébrutinib, aimed at treating non-relapsing secondary progressive multiple sclerosis (nrSPMS), will take longer than the initially set target action date of December 28, 2025. The company expects to receive further guidance from the Food and Drug Administration (FDA) by the end of the first quarter of 2026.
Submission of Expanded Access Protocol
In response to a request from the FDA, Sanofi has submitted an expanded access protocol for tolébrutinib, highlighting its commitment to providing eligible patients access to this experimental treatment. The company expresses its belief in the favorable benefit-risk profile of tolébrutinib for patients with nrSPMS.
About Tolébrutinib
Tolébrutinib is an orally administered Bruton's tyrosine kinase inhibitor, designed to target persistent neuroinflammation, a central element in the progression of multiple sclerosis. This targeted treatment addresses the inflammatory processes responsible for neurodegeneration and the accumulation of disabilities in MS.
